Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy with BRAF and MEK inhibitors is associated with significant long-term treatment benefit in patients with BRAF V600-mutated melanom...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Liang, Lopez-Beltran, Antonio, Massari, Francesco, MacLennan, Gregory T, Montironi, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758899/
https://www.ncbi.nlm.nih.gov/pubmed/29148538
http://dx.doi.org/10.1038/modpathol.2017.104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758899/
https://www.ncbi.nlm.nih.gov/pubmed/29148538
http://dx.doi.org/10.1038/modpathol.2017.104

Ejemplares similares